RWID Multimodal · Pre-built research cohort

The only real-world data platform rooted in imaging, with prebuilt multimodal full-patient cohorts

Explore the datasets
Book a technical call
Pre-built multimodal research cohorts for high-priority therapeutic areas. Imaging, treatment history, outcomes, and biomarkers — ready for biomarker development, clinical trial design, and real-world evidence generation.
31M
Patients in network
150M+
Real world images
studied
3.5M
Patients with
imaging-linked

RWD cohorts

Challenge

The imaging gap in RWD

Real-world evidence without the scan is structurally incomplete

Whether the endpoint is tumor response, amyloid reduction, cardiometabolic outcome, or biomarker progression — biopharma depends on the image. Yet every major real-world data platform is built from EHR, claims, or genomics outward. Imaging is secondary, ingested, or absent entirely.

Segmed is the only RWD platform built from imaging outward, with clinical context layered in at scale. The pre-built research cohorts below bring together imaging, treatment history, outcomes, and biomarkers in the specific therapeutic areas where the need is most acute.

PRISM Pre-Built Research Cohorts

Multimodal datasets for priority therapeutic areas
PRISM Series are our pre-built RWID multimodal cohorts, each engineered for the evidence requirements of its therapeutic area.

GLP-1 Longitudinal Imaging Biomarkers & Outcomes Cohort

Abdominal CT/MRI, DEXA

Metabolic

01

Use Cases

How does this apply to your work?
Each dataset supports four persona-aligned use cases across the drug development lifecycle.
Request datasets

Translational medicine

AI biomarker development requires imaging paired with clinical ground truth. Training data provenance starts at acquisition, not at submission. Build response and progression endpoints on multimodal patient records.

Clinical trial design

Endpoint feasibility, AI reader concordance, and patient selection calibration — validated on real-world imaging data before protocol lock. Model your endpoint distribution across 31M patients.

Post-marketing
surveillance & RWE

Surveillance from the treated population, not the trial population. Real-world response characterization, safety monitoring, and label expansion evidence from community and academic settings.

AI / RWD lead

External training data at pharma scale. Multi-vendor, multi-protocol diversity your internal datasets cannot replicate. From data request to training-ready pipeline in days, not months.

Why Segmed

The structural gap in RWD.
Only Segmed has closed it.
Every major RWD competitor is built EHR-first, claims-first, or genomics-first. No competitor has built from the imaging asset outward with linked clinical context at scale.

Imaging at Scale

Segmed

150M+ studies

Others

Limited or none

Imaging + EHR linkage

Segmed

3.5M patients linked

Others

Partial or absent

Built imaging-first

Privacy-preserving

Segmed

Yes

Segmed

Yes

Others

None

Others

Varies

The Data You Need

Proven in programme-critical applications

Pharma programmes

Supporting Phase III endpoint feasibility and biomarker development for Top 10 pharma programmes across oncology, neurology, and cardiometabolic therapeutic areas.

Published research

Peer-reviewed work on applications of real-world  imaging data for biopharma and life sciences use cases.

Access timeline

Data in days, not months. Compliance infrastructure (de-identification, provenance documentation) managed on the platform.

Dataset Request

Request access to RWID multimodal cohorts
Receive technical specifications for the pre-built research cohort relevant to your programme.

Frequented Asked Questions - F.A.Q.

What is a pre-built multimodal research cohort?

A pre-built multimodal research cohort is a curated dataset that links imaging data (CT, MRI, DEXA, ultrasound) with structured clinical records (demographics, diagnoses, medications, labs, and outcomes) for a defined patient population. "Pre-built" means the cohort is already assembled, de-identified, and quality-controlled, so your team can move from data request to analysis in days rather than spending months on procurement, and data linkage. "Multimodal" means the imaging and clinical records are linked at the patient level, enabling longitudinal analysis that neither data type can support alone.
‍

How is Segmed's approach different from EHR-first RWD platforms?

Most real-world data platforms are built from electronic health records, claims, or genomics outward. Imaging, if available at all, is secondary, ingested after the fact, limited in scale, or disconnected from the clinical record. Segmed is built from imaging outward. The 150M+ real-world imaging studies in the network are the foundation, with clinical context (treatment history, outcomes, labs, biomarkers) linked to the imaging at patient level. For use cases where the scan is the primary evidence (body composition changes on GLP-1 therapy, tumor response, neurodegenerative biomarker trajectories) this architectural difference determines whether the data can answer the question at all.

Close
Close